Key terms
About ETNB
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ETNB news
Apr 17
4:22pm ET
89bio Enhances Board with Biopharma Veteran Martin Babler
Apr 04
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Apr 03
10:52am ET
Biotech Alert: Searches spiking for these stocks today
Mar 29
3:09am ET
Buy Rating Affirmed for 89bio’s Pegozafermin: A Promising NASH Treatment with Strong Regulatory Endorsements
Mar 27
12:30pm ET
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
Mar 27
8:10am ET
89bio receives EMA PRIME status for Pegozafermin
Mar 26
9:06am ET
Insider Trading: RA Capital Buys Stock Worth $15M in LENZ Therapeutics
Mar 18
8:35am ET
5 Stocks that Analysts Love in March 2024
Mar 15
10:26am ET
BofA says 89bio should trade with strength after ‘win for entire MASH space’
Mar 13
10:00am ET
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
Mar 12
8:13am ET
89bio initiates Phase 3 ENLIGHTEN-Fibrosis trial of pegozafermin
Mar 11
3:35pm ET
Fly Insider : Echostar, Dell among week’s notable insider trades
Mar 07
6:32am ET
Insider Trading: Director Boosts Stake in 89bio (NASDAQ:ETNB) Stock
Mar 06
11:19pm ET
Buy Rating Reaffirmed for 89bio with Potential Market Edge in Fibrosis and Metabolic Diseases
Mar 06
1:58pm ET
89bio price target raised to $37 from $29 at Evercore ISI
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
7:21pm ET
Analysts’ Top Healthcare Picks: 89bio (ETNB), UnitedHealth (UNH)
Mar 04
7:02pm ET
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Vicarious Surgical (RBOT) and 89bio (ETNB)
Mar 04
12:10pm ET
Akero 96-week update ‘posiitve’ for 89Bio, says Raymond James
Mar 03
1:00am ET
89Bio Inc Is Worried About This – Should You Be Worried Too?
Mar 01
7:27am ET
RBC Capital Sticks to Their Hold Rating for 89bio (ETNB)
Mar 01
6:27am ET
89bio price target lowered to $31 from $32 at H.C. Wainwright
Feb 29
4:21pm ET
89bio reports Q4 EPS (50c), consensus (49c)
Feb 26
12:02pm ET
Madrigal opportunity in MASH remains after Boehringer data, says UBS
Feb 09
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
1:10pm ET
Cantor biotech/biopharma analysts to hold analyst/industry conference call
No recent press releases are available for ETNB
ETNB Financials
Key terms
Ad Feedback
ETNB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ETNB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
